About this medicine

Doxepin may improve depression and associated sleep disturbance. Its sedative effect can be apparent before its antidepressant effect, so sleepiness alone does not show that depression has responded.

What is this medicine used for?

The checked UK licence concerns depressive illness in adults. It does not authorise every use described in the US edition or establish a low-dose UK insomnia product.

Which warning signs need help?

An overdose can cause fatal heart-rhythm or breathing problems: obtain emergency help even before severe symptoms appear. New self-harm thoughts, severe allergy or seizures require urgent assessment.

Agitation or confusion with fever, sweating, diarrhoea, tremor or muscle overactivity can signal serotonin toxicity, particularly with opioids or other serotonergic medicines. This requires prompt medical assessment, not an assumption that anxiety has worsened.

MHRA’s October 2026 communication announced the rollout of a prominent boxed warning in UK antidepressant patient leaflets about self-harm and suicidal behaviour, alongside a patient safety card. This UK patient-information measure is not the US FDA Boxed Warning designation. Read the leaflet supplied with your medicine, seek prompt professional help for new or worsening mood or behaviour changes, and do not stop treatment suddenly without advice.

How do I take it safely?

The checked UK oral capsule range includes 10 mg, 25 mg and 50 mg strengths. Sinepin is a named UK doxepin capsule product in the checked SmPC. Product information confirms identity and licensed use, not pharmacy stock or NHS funding.

UK product reference: treatment commonly starts at 75 mg daily, with individual adjustment over 25–300 mg daily. No single dose should exceed 100 mg; totals above 100 mg require divided doses. These are product limits, not self-adjustment instructions.

The 10 mg capsule remains licensed for adult depressive illness; its smaller strength is not evidence of a UK sleep-only indication. Do not apply US Silenor instructions or attempt to recreate a different product by dividing capsule contents.

What side effects should I know about?

Drowsiness, dry mouth and constipation are prominent. Weight, sexual function and sweating may also change. Persistent troublesome effects should lead to review, not unplanned discontinuation.

Who needs extra care with this medicine?

Mania, glaucoma, urinary retention, severe liver disease and breastfeeding are exclusions in the checked product. Heart disease, recent heart attack and epilepsy require particular caution.

Can it affect my other medicines?

Do not combine with an MAOI or use within the stated two-week interval. Alcohol, other sedatives and anticholinergic medicines add risk; cimetidine, thyroid medicines and sympathomimetics also need checking.

Tell the anaesthetist before surgery. CYP2D6-inhibiting medicines can increase tricyclic exposure; adding a medicine without changing the doxepin dose can still change the effect.

What check-ups will I need?

Review mood and suicidal thinking early and after changes, especially in younger adults. Monitor tolerability, falls risk and cardiovascular concerns, with investigations guided by the person's risks.

Older adults are particularly vulnerable to confusion and postural hypotension. Antidepressant benefit, sleep, daytime alertness and functioning should be evaluated separately; sedation alone is not the treatment target.

What about pregnancy, breastfeeding and age?

The capsules are for adults; safety and efficacy below 18 are not established. Pregnancy requires an individual discussion. Breastfeeding is contraindicated in these product records because infant sedation and apnoea have been reported.

What if I miss a dose or want to stop?

If a dose is forgotten, take the next scheduled dose normally rather than doubling. Planned gradual reduction can reduce insomnia, irritability and sweating when treatment is stopped.

How does it work?

The way doxepin improves depression is not fully understood. One proposed contribution is slowing the return of noradrenaline, a chemical messenger, into the nerve cells that released it. This return is called reuptake; reducing it can leave more messenger available at some connections between cells. That is a change in communication rather than the simple replacement of a missing chemical.

How Brain Cells Communicate

Nerve cells communicate using chemical messengers called neurotransmitters. Receptors are proteins that respond to these messengers, while transporters carry some messengers back into cells after release. That return process is called reuptake and helps regulate how long a message remains available. Changes in transport and in receptor responses can both affect the activity of connected nerve cells.

What is known: Receptors respond to messengers, while transporters help move them.

What remains uncertain: The activity of one signalling pathway cannot explain all the changes involved in depression.

How the process works

  1. Nerve-cell signal
  2. Receptor or transporter
  3. Network activity
Receptors respond to messengers, while transporters help move them. Simplified illustration of the process; individual responses vary.
About this illustration

Nerve-cell signal; Receptor or transporter; Network activity. The activity of one signalling pathway cannot explain all the changes involved in depression.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How the Medication Changes Signaling

One proposed contribution to doxepin’s antidepressant effect is reduced reuptake of noradrenaline, also called norepinephrine. This can leave more of the messenger available at connections between nerve cells. Laboratory and animal studies also describe effects involving histamine, serotonin and acetylcholine, messengers with roles in wakefulness, mood and physical functions such as bowel activity. Finding several actions does not establish which combination produces improvement in depression.

What is known: Doxepin affects several chemical signalling systems.

What remains uncertain: The link between these actions and antidepressant benefit remains incomplete.

How the process works

  1. Doxepin
  2. Molecular actions
  3. Clinical effects
Doxepin affects several chemical signalling systems. Simplified illustration of the process; individual responses vary.
About this illustration

Doxepin; Molecular actions; Clinical effects. The link between these actions and antidepressant benefit remains incomplete.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

A Closer Look at the Molecular Level

After a capsule is swallowed, doxepin is absorbed from the gut and processed in the liver. This produces desmethyldoxepin, also called nordoxepin, an active metabolite: a substance formed from a medicine that still has drug effects. The amount of the original medicine and metabolite reaching the body over time is called exposure. Liver function and medicines that affect processing enzymes can change this exposure, helping explain why the same amount of medicine can have different effects in different people.

What is known: Doxepin and its active metabolite both remain relevant to the medicine’s effects.

What remains uncertain: Drug levels alone cannot predict the balance of benefit and unwanted effects.

How the process works

  1. Dose and metabolism
  2. Drug exposure
  3. Benefit and harm
Doxepin and its active metabolite both remain relevant to the medicine’s effects. Simplified illustration of the process; individual responses vary.
About this illustration

Dose and metabolism; Drug exposure; Benefit and harm. Drug levels alone cannot predict the balance of benefit and unwanted effects.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How does it affect my body?

Dry mouth, bowel slowing and sedation reflect effects outside mood regulation. Dizziness on standing, blurred vision and urinary difficulty can be particularly troublesome in older people.

How does my body process it?

The liver forms an active metabolite, desmethyldoxepin, which persists longer than the parent medicine. Liver or kidney impairment may therefore require a more cautious regimen.

How do treatment options differ?

A sedating antidepressant is not automatically a general sleep treatment. Products containing the same ingredient can have different licensed purposes and dose ranges.

A closer look at the science

Doxepin belongs to the tricyclic family and also has antihistaminic and anticholinergic actions. Its several actions mean benefit and adverse effects cannot be predicted from one receptor alone.

Doxepin is a dibenzoxepin compound supplied as a hydrochloride mixture of E and Z geometric isomers.

Chemical formula: C19H21NO · HCl

PubChem CID3158 depicts neutral doxepin connectivity, C19H21NO. The product contains E and Z isomers; the drawing does not specify their ratio or represent a single-isomer product.

PubChem 2D depiction of neutral doxepin; salt components omitted.
NCBI PubChem CID 3158. Lines are bonds; unlabeled corners are carbon and many hydrogen atoms are omitted. This neutral-parent drawing is connectivity, not a binding pose.

The drawing shows the neutral parent. The product salt formula is separately identified; neither determines release rate or dose.

How was this medicine developed?

The checked Zentiva authorisation record dates from 2020, with later renewal and revision. These are dates for that product, not the date doxepin was discovered.

Sources and References

  1. Doxepin 25 mg capsules: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  2. Doxepin 25 mg hard capsules: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  3. Doxepin 25 mg and 50 mg capsules: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  4. Antidepressants: use and safety

    Scope: United Kingdom.

  5. Doxepin 10 mg capsules: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  6. Doxepin 50 mg capsules: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  7. Sinepin 25 mg capsules: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  8. Doxepin — UK product-information inventory

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  9. Doxepin: current prescribing information

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  10. What Is a Neurotransmitter? — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: How Neurotransmitters Work; Types of Neurotransmitters..

  11. Silenor: current prescribing information

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  12. Doxepin: verified neutral parent, PubChem CID 3158

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  13. Low blood pressure: MedlinePlus Medical Encyclopedia

Shared scientific background. US product pharmacology and international chemical references do not establish UK licences, doses, formulations or NHS recommendations.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top